DIZAL PHARMACEUTICAL CO., LTD.

迪哲(江苏)医药股份有限公司

Develops and commercializes oncology and hematology drugs in Chinese Mainland, including ZEGFROVY, an EGFR TKI for lung cancer, and golidocitinib, a JAK1 inhibitor, with additional clinical-stage drug candidates.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Leased property
• Social insurance & housing fund
• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Single product, business line or region
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets